Colorado BioScience Association’s Post

After 24 months of collaboration, innovation, and impact, the SYNBEE project is reaching its conclusion! Launched in January 2023, SYNBEE has been a catalyst for progress in #SyntheticBiology, leaving behind an important legacy. 🧬 SYNBEE: A Collaborative Vision 🧬 - Bringing together 15 leading business, research, and academic institutions from 8 countries, the project harnessed the entrepreneurial potential of Synthetic Biology. By complementing each other in background knowledge, technical expertise, and market experience, a truly innovative ecosystem was created to foster entrepreneurial excellence. 📣 The Mission 📣 SYNBEE – the SYNthetic Biology Entrepreneurial Ecosystem – sought to enhance the entrepreneurial and business skills of young professionals across Europe, specifically in Synthetic Biology. The goal was clear: to train future entrepreneurs equipped to start, scale, internationalise, and build companies in this exciting and commercially under-explored industry. 🔢 SYNBEE in Numbers 🔢 - Duration: 24 months of action and growth - Team: 8 beneficiaries, 7 associated partners, and 15 institutions from 8 countries - Funding: Over €990,000 - Output: 28 detailed reports delivered - Events: 2 matchmaking events, 2 mentorship workshops, 2 pitch competitions, and 2 hackathons - Engagement: 3 newsletters launched, 8 training sessions conducted, and 9 interviews filmed These achievements are a testament to the vision and determination of the #community! We extend our deepest gratitude to the European Commission and the European Innovation Council and SMEs Executive Agency (EISMEA) for their unwavering support and funding. Your commitment to fostering innovation and empowering groundbreaking projects like SYNBEE has made it possible to achieve milestones that will resonate far beyond this initiative. _ _ _ #SYNBEE #SYNBEEProject #EUProject #HorizonProject #SyntheticBiology #Entrepreneurship #SYNBEEinNumbers #AlmostEnding #Events #Outputs #Partners #Teamwork #InnovativeEcosystem _ _ _ Da Vinci Labs | Häme University of Applied Sciences, HAMK | Delft University of Technology | Biocatalyst Foundation | F6S Innovation | Rīgas Tehniskā universitāte (Riga Technical University) | TWB | INRAE Transfert SAS | European Synthetic Biology Society (EUSynBioS)

Why grants can make you less driven Europe’s biotech sector has always been fond of government grants. Programs like Horizon Europe, with its eye-watering €95.5 billion budget for research and innovation from 2021 to 2027, have kept the pipettes full and the lab coats spotless. National initiatives in Germany and France add to the mix, ensuring a steady stream of funding for ambitious projects. Yet, for all this largesse, one can’t help but wonder if Europe’s labs are growing a little too comfortable. The problem isn’t the money itself—scientists would happily accept it in unmarked bills if necessary. It’s that the money rarely comes with the right kind of strings attached. Grants lack the hard-nosed accountability of private investment. They create a cozy cushion where risk-taking is optional, commercialization is frowned upon, and innovation is often more paper than product. As a result, Europe produces brilliant ideas but struggles to turn them into world-changing therapies.

Thank you Economic Development Minister Vic Fedeli, MPP Nipissing, (-and still the kindest most approachable guy from the North), and Premier Doug Ford for your leadership and support for Life Sciences in Ontario. I have for years admired how New England and California governments provide support for their Healthcare/Research Ecosystems that create new therapeutics that do improve lives. Ontario can compete if provided the necessary support from Government, VCs, Academia, Entrepreneurs & Skilled Scientists. https://lnkd.in/eAEQKcKP

Dal has received a $32 MILLION grant for a national Lab2Market network! This network for innovation, commercialization and entrepreneurship skills training is a great vote of confidence in the role Dal plays in fostering innovation. It reflects a deep commitment from Dal, industry partners, and government that will allow students and researchers to turn ideas into enterprises. It helps people like alum Dr. Rafaela Andrade (PhD MD'15) (pictured) who leveraged Lab2Market after her PhD in biochemistry at Dalhousie to establish her company Myomar Molecular! Learn more: https://ow.ly/qxgJ50UIKwM Mitacs Lab2Market

𝗪𝗶𝗻𝗻𝗲𝗿 𝗔𝗻𝗻𝗼𝗻𝗰𝗲𝗺𝗲𝗻𝘁, 𝟵𝘁𝗵 𝗲𝗱𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗣𝗿𝗼𝗽𝗲𝗹𝗹𝗶𝗻𝗴 𝗚𝗿𝗮𝗻𝘁 𝗣𝗿𝗼𝗴𝗿𝗮𝗺!  Today, we are thrilled to announce the second winners of the 9th edition of the Propelling Grant, 𝗥𝗘𝘀𝗼𝗹𝘃𝗲! ✨ Last week, we asked the innovators behind 𝗥𝗘𝘀𝗼𝗹𝘃𝗲, Kevin Nils Baumann, Lukas Beckert and Mitchell Brüderlin, how the Propelling Grant supports them to achieve their next goals! Here are their answers & insights! 𝗤𝟭: 𝗖𝗮𝗻 𝘆𝗼𝘂 𝗱𝗲𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗥𝗘𝘀𝗼𝗹𝘃𝗲 𝗮𝗶𝗺𝘀 𝘁𝗼 𝘁𝗮𝗰𝗸𝗹𝗲? “About 90% of clinical trials fail. This is partly attributed to the complexity of detecting off-target effects and other unintended molecular interactions. At 𝗥𝗘𝘀𝗼𝗹𝘃𝗲 we are transforming the way these interactions are measured. Our technology offers an unprecedented level of precision and simplicity in single molecule analysis across the life sciences.” 𝗤𝟮: 𝗛𝗼𝘄 𝗶𝘀 𝘁𝗵𝗲 𝗣𝗿𝗼𝗽𝗲𝗹𝗹𝗶𝗻𝗴 𝗚𝗿𝗮𝗻𝘁 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝘆𝗼𝘂 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝘆𝗼𝘂𝗿 𝗲𝗻𝘁𝗿𝗲𝗽𝗿𝗲𝗻𝗲𝘂𝗿𝗶𝗮𝗹 𝗷𝗼𝘂𝗿𝗻𝗲𝘆? “Beyond offering financial support to our R&D activities, the Propelling Grant provides a unique platform to strengthen our business case and identify our customer base. The close contact with the team at the 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗢𝗳𝗳𝗶𝗰𝗲 plus a whole network of mentors and peers will propel our project to the next level.” 𝗖𝘂𝗿𝗶𝗼𝘂𝘀 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗲𝗱𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗣𝗿𝗼𝗽𝗲𝗹𝗹𝗶𝗻𝗴 𝗚𝗿𝗮𝗻𝘁? It’s open to researchers with an active University of Basel affiliation aiming to transform their discoveries into a startup. Visit here https://lnkd.in/ehn76Dkt for details. 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗧𝗶𝗺𝗲𝗹𝗶𝗻𝗲: ⌛Deadline: 3rd March 2025 (noon) 🗓️Interviews (if selected): 4th April 2025 🤔Deliberation: until mid-May 2025 🚀Program Start: June 2025

As Commissioner confirmations continue, our DG Dr. Claire Skentelbery sat with Ian Mundell, from Science|Business to comment on EuropaBio - the European Association for Bioindustries expectations for the new Commission portfolio for Start-ups, Research, and Innovation.   The EuropaBio - the European Association for Bioindustries DG said, "We know what Europe must be, compared to the global regions that out-compete us. Our scientific breakthroughs deserve better at EU and member state level,”   ➡ Read the full article at: https://lnkd.in/eXsGy4Jf

Looking for your next high-potential investment in life sciences? At Life Science Nation (LSN)'s #RESIConference during #JPM2025 the NIH SEED is showcasing 12 cutting-edge life sciences companies that stand out from the crowd. Here’s what makes them prime investment opportunities: 🔹 De-risked through rigorous scientific review – Backed by the NIH for their innovation and potential. 🔹 Non-dilutive funding secured – Giving them a strong foundation for growth. 🔹 Groundbreaking innovations – At the forefront of biotech, tackling some of the biggest challenges in health and medicine. These companies are positioned for success, but the window to invest in them won’t stay open for long. If you’re serious about finding your next investment in life sciences, you can’t afford to sit this one out. Girish K. of Arborsense, Inc., Donna J. Edmonds of BRAINBox Solutions, Inc. , Marlee Krieger of Calla Health Foundation, Rachel Kuperman of Eysz, Chengcang Wu of Intact Genomics, Inc., Marc Finch of #Pretel, Roarke Horstmeyer and Gregor Horstmeyer of #Romana, Sergio Barberan-Soler and Anne Scholz of RealSeq Biosciences, Anna Lisa Somera of Rhaeos, Michael Giles of Sonara Health, Negin Majedi, PhD of Symphony Biosciences, and Tim Keane of TYBR Health Learn more about these 12 companies at https://lnkd.in/eZnXCqkt ♻️ Share this post to make sure others in your network don’t miss out. Ethel Rubin John Sullivan Anna Zornosa Luis Gutiérrez John P. Reinhart Kuldeep Neote Stephen Flaim, Ph.D., FACC, FAHA Chris S. Olivia Meyer Brittany Connors, PMP Jessica Lukacs, MD, MBA, Emily C. Dennis Ford Max Braht

MassBio’s recently released Vision 2030 plan focuses on strengthening the #LifeScience ecosystem in Massachusetts by creating and retaining jobs, supporting #Biotech startups, and expanding the industry’s capacity for #Biomanufacturing. Download the full report to learn more! https://lnkd.in/eczzKP2i

Are you considering making an application for a grant from The Biotechnology and Biological Sciences Research Council? Capti Innovation, established in 2010, distinguishes itself as the only UK company dedicated to providing extensive support for innovation and technology grants. Our expertise increases your chances of winning grant applications, saving you time and making your proposal stand out. We are dedicated to providing top-quality service with a proven track record of success. Let us help you secure the funding you need for your business goals. Biotechnology and Biological Sciences Research Council, part of UK Research and Innovation, is a non-departmental public body, and is the largest UK public funder of non-medical bioscience. It predominantly funds scientific research institutes and university research departments in the UK. BBSRC was created in 1994, merging the former Agricultural and Food Research Council (AFRC) and taking over the biological science activities of the former Science and Engineering Research Council (SERC). Apply for funding to ‘get out of the lab’ and test your technology in the market to uncover its commercial potential. At Capti Innovation our mission is to make grant funding more accessible. Every year, we help hundreds of companies save time, win funding and accelerate growth by leveraging our extensive expertise in funding opportunities. Email us for more information hello@capti.co.uk #funding #investing #fintech #technology #sustainability #growth #cybersecurity #environment #food #automation #automotive #recycling #nutrition #medicine #robotics #farming #augmentedreality #neuroscience #grants #ukgrants #startupgrants #businessgrants #ukgovernmentgrant #sme #smegrant #businessfunding #smefunding #technologygrant #innovationgrant #capti #captiinnovation #gamechanging #gamechanginginnovation #disruptiveinnovation #smartgrant #ai #manufacturing #sustainable #innovation #telecoms #semiconductors #business #bbsrc

“A few decades ago, Yale’s president, provost, med school dean and other leaders had this vision to establish a preeminent global research institution,” says Jon Soderstrom. “They knew they needed to attract and retain the best and the brightest faculty possible. But those faculty researchers expected that their science wouldn’t end in the lab — that it would lead to disease cures. When it didn’t, they would be recruited away to some place like Cambridge, Massachusetts, or Palo Alto, California." I was hired to stop that, in part by helping the faculty members realize their dreams and aspirations to transform their inventions into commercial products. One of the best ways to do that was to help them start companies based on their science.” Eshelman Innovation Steering Board member Jon Soderstrom is a chief licensing adviser in the New York office of Wilson Sonsini Goodrich & Rosati. Under Jon’s leadership for 25-plus years, Yale Ventures (formerly known as Yale’s Office of Cooperative Research) helped form over 75 new ventures including Achillion Pharmaceuticals, Inc., Arvinas, NextCure, Inc., Biohaven and Inozyme Pharma, which have collectively raised over $1 billion in professional venture capital. In 2001, with his direction, Yale became the first university to monetize its intellectual property when it worked with Royalty Pharma to sell its royalty interest in Zerit, the first FDA-approved drug to effectively treat HIV/AIDS. “For a university to be a global research leader, it’s not enough to publish great science. You need impact, the kind that comes from saving lives and improving quality of life. It involves venture capital and other resources far outside of academia. You must embrace these things and bring them together with the academic research.” Eshelman Innovation would like to thank all members of its Steering Board. Collectively, they bring a wealth of experience and insights from the worlds of biotechnology, digital technology, medicine, venture capital, academia, philanthropy, tech transfer, global public health and more. What a #BrainTrust!